title: [Clinical practice guideline for the diagnosis and treatment of pituitary apoplexy].
abstract: Classic pituitary apoplexy (PA) is an acute, life-threatening clinical syndrome caused by acute hemorrhage and/or infarction of the pituitary gland. PA is considered a neuroendocrinological emergency. However, there is no consensus about the best options for PA diagnosis and management.
  
  
  OBJECTIVE
  To develop a clinical practice guideline with a number of recommendations for diagnosis and treatment of patients with PA based on the medical evidence available, in order to help clinicians involved in their care.
  
  
  METHODS
  The clinical guideline for diagnosis and treatment of pituitary apoplexy issued in 2006 by the Neuroendocrinology Working Group of the Spanish Society of Endocrinology and Nutrition (SEEN) and the British Clinical Practice Guideline published in 2011 were taken as the basis. The text has been adapted to the format used in most international medical journals. For this, after updated medical literature, the quality of evidence and the strength of the recommendations were evaluated using the system proposed by the Agency for Health Care Policy and Research (AHCPR).
  
  
  CONCLUSIONS
  Diagnosis of pituitary apoplexy should be considered in all patients with acute severe headache with or without neuro-ophthalmic signs. Patients with PA must undergo a complete history and physical examination. All patients with suspected pituitary apoplexy should have urgent blood samples drawn to test electrolytes, renal function, liver function, coagulation screen, complete blood count, and basal levels of pituitary and peripheral hormones, and to rule out adrenocorticotropic hormone (ACTH) deficiency. Formal visual field assessment should be performed when the patient is clinically stable. Magnetic resonance imaging (MRI) is the imaging test of choice to confirm diagnosis. Indications for empirical urgent corticosteroid therapy in patients with PA include hemodynamic instability, impaired consciousness, reduced visual acuity, and severe visual field defects. In patients with these severe neuro-ophthalmic signs, surgery should be considered. Surgery should preferably be performed within seven days of the onset of symptoms. Patients with mild and stable signs may be managed conservatively with careful monitoring. Treatment and long-term follow-up of patients with PA should be conducted by a multidisciplinary team consisting, amongst others, of an experienced pituitary neurosurgeon, an ophthalmologist, and an endocrinologist.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, España. Electronic address: almudena@m3d.net.
authors.forename: Almudena
authors.initials: A
authors.lastname: Vicente
authors.forename: Beatriz
authors.initials: B
authors.lastname: Lecumberri
authors.forename: María Ángeles
authors.initials: MÁ
authors.lastname: Gálvez
mesh_terms: D000465:Algorithms; D006801:Humans; D010899:Pituitary Apoplexy / Q000175:diagnosis* / Q000628:therapy*
keywords: (AHRQ) Agencia americana para la política sanitaria y la investigación; ACTH; AH; AHCPR; Apolejía hipofisaria; Apoplectic stroke; Apoplejía hipofisaria; CFNR; CRH; Capa de fibras nerviosas de la retina; GH; GnRH; Hormona adrenocorticotropa; Hormona de crecimiento; Hormona liberadora de corticotropina; Hormona liberadora de gonadotopinas; Ictus apopléctico; Pituitary apoplexy; Pituitary tumor; RM; Resonancia Nuclear Magnética; TC; TCO; Tomografía axial computerizada; Tomografía de coherencia óptica; Tumor hipofisario